Drug Trial Radar · NCT00912964
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
Last checked: Nov 19, 2026Latest source record: Nov 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,030
Actual
Start
Apr 28, 2009
Primary completion
Apr 27, 2010
Study completion Apr 27, 2010
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jun 3, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is intended to test efficacy, safety and tolerability of two doses of once daily (qd) Mirabegron against placebo to treat patients with symptoms of overactive bladder.
Conditions
- Urinary Bladder, Overactive
Interventions
MirabegronDrug
Mirabegron tablets
PlaceboDrug
Matching mirabegron placebo tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to End of Treatment (Final Visit) in Mean Number of Incontinence Episodes Per 24 HoursTime frame: Baseline and Week 12
- Change From Baseline to End of Treatment (Final Visit) in Mean Number of Micturitions Per 24 HoursTime frame: Baseline and Week 12
Locations
151 sites in 11 countries. Site status is shown where the registry gives one.
Site not named
Homewood, Alabama
Site not named
Huntsville, Alabama
Site not named
Mobile, Alabama
Site not named
Chandler, Arizona
Site not named
Tucson, Arizona
Site not named
Tucson, Arizona
Site not named
Little Rock, Arkansas
Site not named
Atherton, California
Site not named
Buena Park, California
Site not named
Fresno, California
Site not named
La Mesa, California
Site not named
Los Angeles, California
Site not named
Newport Beach, California
Site not named
San Bernardino, California
Site not named
San Diego, California
Site not named
Tarzana, California
Site not named
Torrance, California
Site not named
Denver, Colorado
Site not named
New Britain, Connecticut
Site not named
Waterbury, Connecticut
Site not named
Aventura, Florida
Site not named
Clearwater, Florida
Site not named
Clearwater, Florida
Site not named
Lauderdale Lakes, Florida
Site not named
Miami, Florida
Site not named
Pembroke Pines, Florida
Site not named
Pembroke Pines, Florida
Site not named
Sarasota, Florida
Site not named
St. Petersburg, Florida
Site not named
Tallahassee, Florida
Site not named
Wellington, Florida
Site not named
West Palm Beach, Florida
Site not named
Alpharetta, Georgia
Site not named
Roswell, Georgia
Site not named
Melrose Park, Illinois
Site not named
Fort Wayne, Indiana
Site not named
Jeffersonville, Indiana
Site not named
West Des Moines, Iowa
Site not named
Overland Park, Kansas
Site not named
Wichita, Kansas
Showing 40 of 151 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.